1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Cash & equivalents declining -2.60% while Biotechnology shows -3.29% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Cash + STI yoy growth 0.5-0.75x the Biotechnology median of -4.77%. Guy Spier would be cautious about potential underfunding of liquidity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-2.19%
0.5-0.75x the Biotechnology median of -3.69%. Guy Spier might worry about liquidity trailing peers.
-4.69%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
0.75-0.9x Biotechnology median of -2.66%. John Neff wonders if the firm invests less in expansions vs. peers.
28.73%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
27.69%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-27.69%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
27.28%
Above 1.5x Biotechnology median of 1.90%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
4.72%
Above 1.5x Biotechnology median of 0.36%. Jim Chanos suspects an alarming rise in overall leverage.
4.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.83%
0.75-0.9x Biotechnology median of -4.27%. John Neff wonders if the firm lags peers in reinvested profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
1.25-1.5x Biotechnology median of -5.52%. Mohnish Pabrai notes above-average net worth expansion.
-2.25%
0.75-0.9x Biotechnology median of -2.87%. John Neff wonders if expansions lag peers.
0.67%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-0.77%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
2.64%
Below half of Biotechnology median 7.07%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
